J&J shot 85.4% effective against severe COVID-19

February 25, 2021 12:00 am | Updated 06:03 am IST - Washington

FDA may authorise single-dose vaccine

No allergic reactions:Vials of Johnson & Johnson’s single-dose vaccine.File Photo

No allergic reactions:Vials of Johnson & Johnson’s single-dose vaccine.File Photo

The single-shot Johnson & Johnson (J&J) vaccine is highly effective in preventing severe COVID-19, including newer variants, according to documents released by the U.S. Food and Drug Administration (FDA) on Wednesday.

The news came as the regulator was set to convene an independent panel Friday that will likely vote to authorise the vaccine, making it the third one available in the country hit hardest by the coronavirus pandemic.

In large clinical trials, the J&J vaccine’s efficacy against severe disease was 85.9% in the United States, 81.7% in South Africa, and 87.6% in Brazil. Overall, among 39,321 participants across all regions, the efficacy against severe COVID-19 was 85.4%, but it fell to 66.1% when including moderate forms of the disease.

Crucially, analysis of different demographic groups revealed no marked differences across age, race, or people with underlying conditions.

The vaccine was generally well-tolerated, with no reports of severe allergic reactions such as anaphylaxis, which have been seen in rare cases for the Pfizer and Moderna shots.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.